Virenc AB has identified and developed novel types of antiviral plantaracins that effectively inhibit and kill several pathogenic viruses including corona and influenza strains. The lead substance, the plantaracin PLNC8αβ, has shown remarkably positive results. Our products will offer new ways to treat virus infections, e.g. respiratory and skin infections, and reduce the financial load on the healthcare sector. Initially, our development efforts are focused on creating a nasal spray and a cream.

Virenc Nasal Spray
A priority product for development is a broad-spectrum over-the-counter (OTC) nasal spray, designed to target Influenza. Coronavirus and Respiratory syncytial viruses. It is especially suited for individuals at "high risk," but will be safe and effective for use by anyone.

Virenc Cream
We are developing a topical cream aimed at treating various viral conditions such as:

- Herpes labialis (cold sores) – caused by herpes simplex virus type 1 (HSV-1).
- Genital herpes – caused by herpes simplex virus type 2 (HSV-2).
- Shingles - caused by the varicella-zoster virus (VZV) – also responsible for chickenpox.
- Human papillomavirus (HPV) – causes warts, including common warts and genital warts.
- Molluscum contagiosum – a skin infection caused by a poxvirus, primarily affecting children but also seen in adults.